COLL

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AMRX SUPN KNSA ALKS INDV LNTH BHC HRMY TEVA VTRS

| Held by: IJR IWM VTI AVUV VXF IWO IJT SPSM PJP CALF

Scroll to Statements

Index	RUT
Market Cap	1.18B
Enterprise Value	1.67B
Income	74.95M
Sales	796.33M
Book/sh	9.64
Cash/sh	13.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	423
IPO	May 07, 2015

P/E	17.84
Forward P/E	4.85
PEG	-
P/S	1.48
P/B	3.78
P/C	2.68
P/FCF	3.58
EV/EBITDA	4.00
EV/Sales	2.10
Quick Ratio	1.62
Current Ratio	1.71
Debt/Eq	2.98
LT Debt/Eq	2.87
Option/Short	Yes / Yes

EPS (ttm)	2.04
EPS next Y	7.51
EPS next Q	1.73
EPS this Y	4.89%
EPS next Y	-3.50%
EPS next 5Y	-6.63%
EPS past 3/5Y	- 17.92%
Sales past 3/5Y	18.94% 20.28%
EPS Y/Y TTM	73.61%
Sales Y/Y TTM	19.88%
EPS Q/Q	442.39%
Sales Q/Q	8.87%
Earnings	May 07 BMO
EPS/Sales Surpr.	15.49% 4.91%

Insider Own	2.19%
Insider Trans	-10.27%
Inst Own	122.92%
Inst Trans	6.56%
ROA	4.57%
ROE	27.41%
ROIC	6.20%
Gross Margin	60.68%
Oper. Margin	24.16%
Profit Margin	9.41%
SMA20	3.88%
SMA50	5.70%
SMA200	-7.06%
Trades

Shs Outstand	32.41M
Shs Float	31.72M
Short Float	16.80%
Short Ratio	11.44
Short Interest	5.33M
52W High	50.79 -28.25%
52W Low	29.19 24.84%
Volatility	4.33% 3.99%
ATR (14)	1.50
RSI (14)	57.39
Beta	0.73
Rel Volume	1.01
Avg Volume	465.67K
Volume	471,280

Perf Week	1.28%
Perf Month	11.47%
Perf Quarter	11.81%
Perf Half Y	-19.96%
Perf YTD	-21.30%
Perf Year	17.93%
Perf 3Y	67.62%
Perf 5Y	59.06%
Perf 10Y	191.52%
Recom	1.60
Target Price	53.60
Prev Close	37.47
Price	36.44
Change	-2.75%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$58
Jan-10-25	Upgrade	Needham	Hold → Buy	$46
Jul-30-24	Upgrade	H.C. Wainwright	Neutral → Buy	$47
Jun-07-24	Upgrade	Jefferies	Hold → Buy	$41 → $44
May-10-24	Downgrade	Piper Sandler	Overweight → Neutral	$39
May-10-24	Downgrade	Needham	Buy → Hold
Jan-04-24	Downgrade	Jefferies	Buy → Hold	$30 → $37
Aug-25-23	Reiterated	Needham	Buy	$35 → $36
May-02-23	Resumed	Jefferies	Buy	$30
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$18 → $26
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$29 → $33
Jul-14-20	Initiated	BWS Financial	Sell	$8
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy	$43
Oct-30-19	Reiterated	Needham	Buy	$33 → $25
May-03-19	Resumed	H.C. Wainwright	Buy	$23
Apr-12-19	Resumed	Janney	Buy	$29
Mar-20-19	Initiated	SunTrust	Hold	$22

Show Previous Ratings

Jun-05-26 08:00AM	Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-27-26 08:00AM	Collegium to Participate in 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 07:31AM	Collegium Completes Acquisition of AZSTARYS from Corium Therapeutics (GlobeNewswire)
May-07-26 04:52PM	Collegium Pharmaceutical, Inc. Q1 2026 Earnings Call Summary (Moby) +7.72%
07:54AM	Collegium Pharmaceutical: Q1 Earnings Snapshot (Associated Press)
07:30AM	Loading…
07:30AM	Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Apr-23-26 08:00AM	Collegium to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-08-26 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-19-26 08:00AM	Collegium to Acquire AZSTARYS from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory (GlobeNewswire)
Mar-10-26 09:04AM	Collegium Pharmaceutical, Inc. (COLL) Surged Following Record Quarterly Results (Insider Monkey)
Mar-05-26 08:00AM	Collegium to Present New Real-World Data at PainConnect 2026 (GlobeNewswire) -5.88%
Mar-03-26 08:00AM	Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community (GlobeNewswire)
Mar-02-26 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-27-26 03:20PM	Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today (StockStory) -5.77%
Feb-26-26 04:32PM	Collegium Pharmaceutical, Inc. Q4 2025 Earnings Call Summary (Moby)
04:13PM	Loading…
04:13PM	Collegium Pharmaceutical Inc (COLL) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:30PM	Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
12:15PM	Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates (Zacks)
09:16AM	Collegium Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
07:53AM	Collegium Pharmaceutical: Q4 Earnings Snapshot (Associated Press Finance)
07:36AM	Collegium Pharmaceutical's (NASDAQ:COLL) Q4 CY2025 Earnings Results: Revenue In Line With Expectations (StockStory)
07:30AM	Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 10:07PM	Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect (StockStory)
10:00AM	Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-23-26 08:00AM	Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical (GlobeNewswire)
Feb-19-26 10:00AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:53AM	Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? (Zacks)
08:15AM	Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-18-26 04:07AM	Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio (Insider Monkey)
Feb-12-26 08:00AM	Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
08:00AM	Loading…
Jan-15-26 08:00AM	Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference (GlobeNewswire)
Jan-12-26 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks) +5.73%
Jan-08-26 08:00AM	Collegium Provides 2026 Financial Guidance and Business Update (GlobeNewswire)
Jan-05-26 09:54AM	Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Jan-02-26 11:22AM	Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio (Zacks)
Dec-31-25 01:04PM	Why You Should Add Encompass Health to Your Portfolio Now (Zacks)
11:24AM	Here's Why You Should Retain Community Health Stock for Now (Zacks)
Dec-30-25 08:00AM	Collegium Announces the Closing of $980 Million Syndicated Credit Facility (GlobeNewswire)
Dec-28-25 11:01PM	2 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Dec-26-25 01:42PM	Here's Why Investors Should Hold Ensign Group Stock for Now (Zacks)
Dec-22-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? (Zacks)
Dec-18-25 11:35PM	3 Unpopular Stocks We Find Risky (StockStory)
05:12AM	Best Value Stocks to Buy for Dec. 18 (Zacks)
Dec-14-25 10:31PM	Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
Dec-11-25 11:34PM	1 Growth Stock Set to Flourishand 2 Facing Challenges (StockStory)
12:51PM	MOH, Aeroflow Team Up to Offer Virtual Diabetes Care in South Carolina (Zacks)
Dec-04-25 09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
09:40AM	Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-03-25 03:45PM	Ensign Group Expands Foothold in Three U.S. States With Facility Buyouts (Zacks)
Nov-21-25 08:04AM	Why 2025 is a Dynamic and Transformative Year for Collegium (Zacks)
Nov-19-25 08:23AM	Collegium Pharma and Entegris have been highlighted as Zacks Bull and Bear of the Day (Zacks)
04:00AM	Bull of the Day: Collegium Pharmaceutical (COLL) (Zacks)
Nov-18-25 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-13-25 12:36AM	5 Revealing Analyst Questions From Collegium Pharmaceutical's Q3 Earnings Call (StockStory)
Nov-12-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.60%
Nov-07-25 09:50AM	COLL Q3 Deep Dive: Jornay PM Momentum and Pain Portfolio Drive Upgraded Outlook (StockStory)
Nov-06-25 03:25PM	Why Are Collegium Pharmaceutical (COLL) Shares Soaring Today (StockStory) +13.42%
02:09PM	Collegium Pharmaceutical Inc (COLL) Q3 2025 Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
09:30AM	Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates (Zacks)
08:09AM	Collegium Pharmaceutical (NASDAQ:COLL) Delivers Impressive Q3, Stock Jumps 12.1% (StockStory)
07:47AM	Collegium Pharmaceutical: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance (GlobeNewswire)
Nov-04-25 10:22PM	Earnings To Watch: Collegium Pharmaceutical (COLL) Reports Q3 Results Tomorrow (StockStory)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
Oct-30-25 10:00AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-29-25 08:00AM	Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment (GlobeNewswire)
Oct-23-25 08:00AM	Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
12:02AM	Collegium Pharmaceutical (COLL): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Oct-22-25 08:00AM	Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences (GlobeNewswire)
Oct-13-25 08:00AM	Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing (GlobeNewswire)
Oct-08-25 11:25AM	Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory (Insider Monkey)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks)
Sep-25-25 07:19PM	Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI (Zacks)
12:00PM	All You Need to Know About Collegium Pharmaceutical (COLL) Rating Upgrade to Strong Buy (Zacks)
Sep-24-25 11:31PM	Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
Sep-23-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Argenx (ARGX) This Year? (Zacks)
Sep-02-25 04:07AM	Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025 (Insider Monkey)
Aug-29-25 05:07AM	Collegium Pharmaceutical, Inc. (COLL) Highlights Real-World Evidence at PAINWeek 2025 (Insider Monkey)
Aug-28-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 08:00AM	Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting (GlobeNewswire)
Aug-14-25 01:34AM	The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical's Q2 Earnings Call (StockStory)
Aug-12-25 03:25AM	COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure (StockStory)
Aug-11-25 09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 02:53PM	Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2% (StockStory) +10.72%
09:30AM	Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:49AM	Collegium Pharmaceutical: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook (GlobeNewswire)
Aug-06-25 05:50PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 11:11PM	Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect (StockStory)
10:00AM	Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-31-25 10:00AM	Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards? (Zacks)
Jul-28-25 12:01AM	3 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Jul-25-25 09:55AM	Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High? (Zacks)
09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)

Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

CEOMr. Vikram Karnani

Executive VP & CFOMs. Colleen Tupper

Executive VPMr. David Dieter

M.D.Dr. Thomas B. Smith FAAFP

Head of Investor RelationsMr. Ian Karp M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SANTINI GINO	Director	Jun 08 '26	Option Exercise	16.49	8,700	143,463	112,483	Jun 10 04:10 PM
Freund John Gordon	Director	May 18 '26	Sale	34.05	20	681	83,952	May 20 04:05 PM
Freund John Gordon	Director	May 15 '26	Option Exercise	16.49	8,700	143,463	88,099	May 18 04:15 PM
Freund John Gordon	Director	May 15 '26	Sale	34.54	4,127	142,547	83,972	May 18 04:15 PM
Freund John Gordon	Director	May 18 '26	Proposed Sale	34.05	30	1,022		May 18 04:07 PM
Lurker Nancy	Director	May 13 '26	Sale	35.97	4,500	161,861	18,017	May 15 04:05 PM
Freund John Gordon	Director	May 15 '26	Proposed Sale	34.54	4,127	142,547		May 15 10:51 AM
BOHLIN GAREN G	Director	May 11 '26	Option Exercise	16.49	8,700	143,463	70,959	May 13 04:05 PM
BOHLIN GAREN G	Director	May 11 '26	Sale	37.18	8,700	323,491	62,259	May 13 04:05 PM
Lurker Nancy	Director	May 13 '26	Proposed Sale	35.97	4,500	161,861		May 13 12:09 PM
BOHLIN GAREN G	Director	May 11 '26	Proposed Sale	37.18	8,700	323,491		May 11 11:38 AM
Dieter David	EVP & General Counsel	Mar 18 '26	Sale	34.92	13,976	488,099	77,071	Mar 20 05:14 PM
Dieter David	Officer	Mar 18 '26	Proposed Sale	34.92	13,976	488,099		Mar 18 04:10 PM
Dieter David	Officer	Mar 09 '26	Proposed Sale	36.65	6,224	228,110		Mar 09 10:39 AM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 03 '26	Sale	40.41	49,976	2,019,437	71,770	Mar 05 04:29 PM
Dreyer Scott	Officer	Mar 03 '26	Proposed Sale	40.41	49,976	2,019,439		Mar 03 04:10 PM
RITA BALICE-GORDON	DIRECTOR	Dec 05 '25	Proposed Sale	47.03	3,650	171,673		Dec 17 04:01 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Option Exercise	15.90	17,600	279,840	121,213	Dec 10 04:32 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Sale	48.17	17,600	847,855	103,613	Dec 10 04:32 PM
Balice-Gordon Rita J.	Director	Dec 05 '25	Sale	47.03	3,650	171,673	52,629	Dec 09 04:22 PM
Dreyer Scott	Officer	Dec 08 '25	Proposed Sale	48.17	17,600	847,855		Dec 08 04:11 PM
Fallon John A.	Director	Nov 12 '25	Option Exercise	12.41	34,853	432,578	99,487	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Sale	47.21	34,853	1,645,536	64,634	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Proposed Sale	47.21	34,853	1,645,536		Nov 12 04:29 PM
Tupper Colleen	EVP & Chief Financial Officer	Nov 06 '25	Sale	40.53	30,000	1,215,753	126,667	Nov 07 04:23 PM
Tupper Colleen	Officer	Nov 06 '25	Proposed Sale	40.53	30,000	1,215,754		Nov 06 04:11 PM
Smith Thomas B	EVP and Chief Medical Officer	Aug 29 '25	Sale	38.42	17,478	671,576	70,264	Sep 03 04:56 PM
Smith Thomas B	Officer	Aug 29 '25	Proposed Sale	38.42	17,478	671,576		Aug 29 02:12 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Option Exercise	21.34	16,389	349,741	120,002	Aug 20 04:57 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Sale	38.21	16,389	626,171	103,613	Aug 20 04:57 PM
SANTINI GINO	Director	Aug 15 '25	Option Exercise	13.45	15,000	201,750	100,447	Aug 19 05:10 PM
SANTINI GINO	Director	Aug 15 '25	Sale	37.19	5,405	201,018	95,042	Aug 19 05:10 PM
Dreyer Scott	Officer	Aug 18 '25	Proposed Sale	38.21	16,389	626,170		Aug 18 04:50 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Option Exercise	21.34	4,861	103,734	108,474	Aug 15 05:08 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Sale	38.03	4,861	184,881	103,613	Aug 15 05:08 PM
Rubric Capital Management LP	10% Owner	Aug 13 '25	Sale	37.85	25,000	946,250	3,132,743	Aug 15 04:12 PM
SANTINI GINO	Director	Aug 15 '25	Proposed Sale	37.19	5,405	201,019		Aug 15 12:34 PM
Dreyer Scott	Officer	Aug 13 '25	Proposed Sale	38.03	4,861	184,881		Aug 13 04:31 PM
Freund John Gordon	Director	Aug 08 '25	Sale	34.36	11,659	400,641	23,129	Aug 12 05:18 PM
Heffernan Michael Thomas	Former Director	Jul 09 '25	Proposed Sale	32.17	10,328	332,269		Jul 09 04:10 PM
Heffernan Michael Thomas	Former Director	Jul 08 '25	Proposed Sale	31.38	790	24,792		Jul 08 04:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Collegium Pharmaceutical Inc

Upgrade your Finviz experience